SCHEMBL17284646

SCHEMBL17284646

CSCCN1CCNCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CXCR4 P61073 2/20 0.43
HSD17B10 Q99714 1/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
SIGMAR1 Q99720 4/20 0.37
RAD52 P43351 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
PHGDH O43175 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
LMNA P02545 1/20 0.33
KDM1A O60341 1/20 0.33
CHRM5 P08912 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17271445 0.98 SMN1; SMN2 (0.43) POLBSMN1; SMN2CXCR4HSD17B10ALDH1A1
SCHEMBL28302065 0.98 CXCR4 (0.47) POLBSMN1; SMN2CXCR4HSD17B10ALDH1A1
SCHEMBL31194975 0.98 POLB (0.43) POLBSMN1; SMN2CXCR4HSD17B10ALDH1A1
SCHEMBL28341030 0.86 CXCR4 (0.50) POLBSMN1; SMN2CXCR4HSD17B10ALDH1A1
SCHEMBL28341011 0.83 CXCR4 (0.55) POLBSMN1; SMN2CXCR4ALDH1A1KDM4E
SCHEMBL31194972 0.82 ALOX15 (0.38) ALDH1A1MEN1KMT2A
SCHEMBL1904154 0.80 POLB (0.48) POLBSMN1; SMN2CXCR4HSD17B10ALDH1A1
Tert-Butyl Formate SCHEMBL28119754 0.80 TDP1 (0.39) POLBSMN1; SMN2CXCR4ALDH1A1KDM4E
SCHEMBL14460636 0.77 POLB (0.42) POLBSMN1; SMN2CXCR4HSD17B10ALDH1A1
SCHEMBL10061913 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615842-A1 TOLL-LIKE RECEPTOR 7 AGONISTS AS IMMUNE-STIMULATORS TO ELICIT THE INNATE ANTITUMOR IMMUNITY Merck Patent GmbH (DE) 2025-09-17 EP disclosed
WO-2024100093-A1 TOLL-LIKE RECEPTOR 7 AGONISTS AS IMMUNE-STIMULATORS TO ELICIT THE INNATE ANTITUMOR IMMUNITY MERCK PATENT GMBH (DE) 2024-05-16 WO disclosed
US-20230382907-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2023-11-30 US disclosed
US-11807638-B2 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases ENLIVEN INC. (US) 2023-11-07 US disclosed
US-11767321-B2 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases ENLIVEN INC. (US) 2023-09-26 US disclosed
US-20230130724-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2023-04-27 US disclosed
WO-2022253283-A1 PROTEIN KINASE DEGRADANT AND USE THEREOF 中国科学院上海有机化学研究所 2022-12-08 WO disclosed
EP-3145929-B1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS HOFFMANN LA ROCHE (CH) 2021-01-13 EP disclosed
EP-2900666-B1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECH LTD (GB) 2020-11-04 EP disclosed
CN-109970743-A 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds as JAK inhibitors 豪夫迈·罗氏有限公司 2019-07-05 CN disclosed
US-9604984-B2 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2017-03-28 US disclosed
US-9604984-B2 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2017-03-28 US disclosed
CN-106459039-A 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds as JAK inhibitors 豪夫迈·罗氏有限公司 2017-02-22 CN disclosed
US-20160237086-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-08-18 US disclosed
US-20160237086-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-08-18 US disclosed
WO-2015177326-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2015-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11807638-B2 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases ABL1, ABL2, BCR POLB 2885/4885SMN1; SMN2 3904/4885CXCR4 1497/4885
US-20230382907-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR POLB 2885/4885SMN1; SMN2 3904/4885CXCR4 1497/4885
US-11767321-B2 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases ABL1, ABL2, BCR POLB 2885/4885SMN1; SMN2 3904/4885CXCR4 1497/4885
US-20230130724-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR POLB 2885/4885SMN1; SMN2 3904/4885CXCR4 1497/4885
US-20160237086-A1 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF ABL1, JAK2, FLT3 POLB 339/4885SMN1; SMN2 3594/4885CXCR4 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.